---
document_datetime: 2025-12-29 14:32:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ivozall.html
document_name: ivozall.html
version: success
processing_time: 0.1107021
conversion_datetime: 2025-12-30 19:58:03.965313
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ivozall

[RSS](/en/individual-human-medicine.xml/67252)

##### Withdrawn

This medicine's authorisation has been withdrawn

clofarabine Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ivozall](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 18 October 2023, the European Commission withdrew the marketing authorisation for Ivozall (clofarabine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, ORPHELIA Pharma SAS, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Ivozall was granted marketing authorisation in the EU on 14 November 2019 for treatment of acute lymphoblastic leukaemia. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since 2022.

Ivozall is a generic medicine of Evoltra. There are other generic medicinal products of Evoltra authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Ivozall is updated to indicate that the marketing authorisation is no longer valid.

Ivozall : EPAR - Medicine overview

Reference Number: EMA/519636/2019

English (EN) (168.14 KB - PDF)

**First published:** 22/11/2019

**Last updated:** 07/12/2023

[View](/en/documents/overview/ivozall-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-276)

български (BG) (216.22 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/bg/documents/overview/ivozall-epar-medicine-overview_bg.pdf)

español (ES) (166.19 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/es/documents/overview/ivozall-epar-medicine-overview_es.pdf)

čeština (CS) (202.08 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/cs/documents/overview/ivozall-epar-medicine-overview_cs.pdf)

dansk (DA) (161.04 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/da/documents/overview/ivozall-epar-medicine-overview_da.pdf)

Deutsch (DE) (168.12 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/de/documents/overview/ivozall-epar-medicine-overview_de.pdf)

eesti keel (ET) (154.3 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/et/documents/overview/ivozall-epar-medicine-overview_et.pdf)

ελληνικά (EL) (229.12 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/el/documents/overview/ivozall-epar-medicine-overview_el.pdf)

français (FR) (166.85 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/fr/documents/overview/ivozall-epar-medicine-overview_fr.pdf)

hrvatski (HR) (185.94 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/hr/documents/overview/ivozall-epar-medicine-overview_hr.pdf)

italiano (IT) (162.29 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/it/documents/overview/ivozall-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (202.84 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/lv/documents/overview/ivozall-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (192.05 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/lt/documents/overview/ivozall-epar-medicine-overview_lt.pdf)

magyar (HU) (190.88 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/hu/documents/overview/ivozall-epar-medicine-overview_hu.pdf)

Malti (MT) (203.71 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/mt/documents/overview/ivozall-epar-medicine-overview_mt.pdf)

Nederlands (NL) (167.6 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/nl/documents/overview/ivozall-epar-medicine-overview_nl.pdf)

polski (PL) (198 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/pl/documents/overview/ivozall-epar-medicine-overview_pl.pdf)

português (PT) (164.09 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/pt/documents/overview/ivozall-epar-medicine-overview_pt.pdf)

română (RO) (206.05 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/ro/documents/overview/ivozall-epar-medicine-overview_ro.pdf)

slovenčina (SK) (190.95 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/sk/documents/overview/ivozall-epar-medicine-overview_sk.pdf)

slovenščina (SL) (186.41 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/sl/documents/overview/ivozall-epar-medicine-overview_sl.pdf)

Suomi (FI) (157.35 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/fi/documents/overview/ivozall-epar-medicine-overview_fi.pdf)

svenska (SV) (160.74 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/sv/documents/overview/ivozall-epar-medicine-overview_sv.pdf)

Ivozall : EPAR - Risk-management-plan summary

English (EN) (173.69 KB - PDF)

**First published:** 22/11/2019

**Last updated:** 07/12/2023

[View](/en/documents/rmp-summary/ivozall-epar-risk-management-plan-summary_en.pdf)

## Product information

Ivozall : EPAR - Product Information

English (EN) (1.38 MB - PDF)

**First published:** 22/11/2019

**Last updated:** 07/12/2023

[View](/en/documents/product-information/ivozall-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-662)

български (BG) (1.93 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/bg/documents/product-information/ivozall-epar-product-information_bg.pdf)

español (ES) (1.6 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/es/documents/product-information/ivozall-epar-product-information_es.pdf)

čeština (CS) (1.6 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/cs/documents/product-information/ivozall-epar-product-information_cs.pdf)

dansk (DA) (1.39 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/da/documents/product-information/ivozall-epar-product-information_da.pdf)

Deutsch (DE) (1.63 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/de/documents/product-information/ivozall-epar-product-information_de.pdf)

eesti keel (ET) (1.38 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/et/documents/product-information/ivozall-epar-product-information_et.pdf)

ελληνικά (EL) (2.05 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/el/documents/product-information/ivozall-epar-product-information_el.pdf)

français (FR) (1.53 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/fr/documents/product-information/ivozall-epar-product-information_fr.pdf)

hrvatski (HR) (1.64 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/hr/documents/product-information/ivozall-epar-product-information_hr.pdf)

íslenska (IS) (1.45 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/is/documents/product-information/ivozall-epar-product-information_is.pdf)

italiano (IT) (1.49 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/it/documents/product-information/ivozall-epar-product-information_it.pdf)

latviešu valoda (LV) (1.78 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/lv/documents/product-information/ivozall-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.77 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/lt/documents/product-information/ivozall-epar-product-information_lt.pdf)

magyar (HU) (1.65 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/hu/documents/product-information/ivozall-epar-product-information_hu.pdf)

Malti (MT) (1.91 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/mt/documents/product-information/ivozall-epar-product-information_mt.pdf)

Nederlands (NL) (1.5 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/nl/documents/product-information/ivozall-epar-product-information_nl.pdf)

norsk (NO) (1.37 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/no/documents/product-information/ivozall-epar-product-information_no.pdf)

polski (PL) (1.85 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/pl/documents/product-information/ivozall-epar-product-information_pl.pdf)

português (PT) (1.51 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/pt/documents/product-information/ivozall-epar-product-information_pt.pdf)

română (RO) (1.93 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/ro/documents/product-information/ivozall-epar-product-information_ro.pdf)

slovenčina (SK) (1.75 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/sk/documents/product-information/ivozall-epar-product-information_sk.pdf)

slovenščina (SL) (1.65 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/sl/documents/product-information/ivozall-epar-product-information_sl.pdf)

Suomi (FI) (1.42 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/fi/documents/product-information/ivozall-epar-product-information_fi.pdf)

svenska (SV) (1.46 MB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/sv/documents/product-information/ivozall-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0006 06/03/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ivozall : EPAR - All authorised presentations

English (EN) (41.03 KB - PDF)

**First published:** 22/11/2019

**Last updated:** 07/12/2023

[View](/en/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-535)

български (BG) (68.66 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/bg/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.68 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/es/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_es.pdf)

čeština (CS) (60.53 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/cs/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.01 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/da/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (42.28 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/de/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (42.25 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/et/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (67.88 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/el/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_el.pdf)

français (FR) (42.42 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/fr/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (58.09 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/hr/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.21 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/is/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_is.pdf)

italiano (IT) (42.35 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/it/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (63.12 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/lv/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (58.29 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/lt/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (50.57 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/hu/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (62.56 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/mt/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (41.67 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/nl/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (44.81 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/no/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_no.pdf)

polski (PL) (60.33 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/pl/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_pl.pdf)

português (PT) (42.7 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/pt/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_pt.pdf)

română (RO) (63.09 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/ro/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (58.86 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/sk/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (51.31 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/sl/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (41.19 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/fi/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (42.52 KB - PDF)

**First published:**

22/11/2019

**Last updated:**

07/12/2023

[View](/sv/documents/all-authorised-presentations/ivozall-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ivozall Active substance clofarabine International non-proprietary name (INN) or common name clofarabine Therapeutic area (MeSH) Precursor Cell Lymphoblastic Leukemia-Lymphoma Anatomical therapeutic chemical (ATC) code L01BB06

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ? 21 years old at initial diagnosis.

## Authorisation details

EMA product number EMEA/H/C/005039

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

ORPHELIA Pharma

85 Boulevard Saint-Michel

Opinion adopted 19/09/2019 Marketing authorisation issued 14/11/2019 Withdrawal of marketing authorisation 18/10/2023 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ivozall : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (246.43 KB - PDF)

**First published:** 05/10/2020

**Last updated:** 07/12/2023

[View](/en/documents/procedural-steps-after/ivozall-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Ivozall-H-C-PSUSA-00000805-201912 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/517911/2020

English (EN) (171.6 KB - PDF)

**First published:** 05/10/2020

**Last updated:** 07/12/2023

[View](/en/documents/scientific-conclusion/ivozall-h-c-psusa-00000805-201912-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Ivozall : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/585665/2019

English (EN) (1.09 MB - PDF)

**First published:** 22/11/2019

**Last updated:** 07/12/2023

[View](/en/documents/assessment-report/ivozall-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ivozall

Adopted

Reference Number: EMA/CHMP/494372/2019

English (EN) (130.24 KB - PDF)

**First published:** 20/09/2019

**Last updated:** 07/12/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ivozall_en.pdf)

#### News on Ivozall

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019) 20/09/2019

**This page was last updated on** 07/12/2023

## Share this page

[Back to top](#main-content)